Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Currently, as dangerous mutations emerge, there is an increased demand for specific treatments for SARS-CoV-2 infected patients. The spike glycoprotein on the virus envelope binds to the angiotensin converting enzyme 2 (ACE2) on host cells through its receptor binding domain (RBD) to mediate virus entry. Thus, blocking this interaction may inhibit viral entry and consequently stop infection. Here, we generated fusion proteins composed of the extracellular portions of ACE2 and RBD fused to the Fc portion of human IgG1 (ACE2-Ig and RBD-Ig, respectively). We demonstrate that ACE2-Ig is enzymatically active and that it can be recognized by the SARS-CoV-2 RBD, independently of its enzymatic activity. We further show that RBD-Ig efficiently inhibits in-vivo SARS-CoV-2 infection better than ACE2-Ig. Mechanistically, we show that anti-spike antibody generation, ACE2 enzymatic activity, and ACE2 surface expression were not affected by RBD-Ig. Finally, we show that RBD-Ig is more efficient than ACE2-Ig at neutralizing high virus titers. We thus propose that RBD-Ig physically blocks virus infection by binding to ACE2 and that RBD-Ig should be used for the treatment of SARS-CoV-2-infected patients. Author summary SARS-CoV-2 has caused serious socio-economic and health problems around the globe. As dangerous mutations emerge there is an increased demand for specific treatments for SARS-CoV-2 infected patients. SARS-CoV-2 infection starts via binding of SARS-CoV-2 spike protein’s receptor binding domain (RBD) to its receptor, ACE2, on host cells. To intercept this binding, we generated Ig-fusion proteins; ACE2-Ig was generated to block the RBD and RBD-Ig generated to block ACE2. We showed that the fusion proteins bind to their respective target and demonstrated both in-vitro and in-vivo that it is more efficient to inhibit SARS-CoV-2 infection by blocking ACE2 receptor with RBD-Ig. We further showed that RBD-Ig does not interfere with ACE2 activity or with its surface expression. We propose that RBD-Ig physically blocks virus infection by binding to ACE2 and thus it may be used for the treatment of SARS-CoV-2-infected patients.
【초록키워드】 Treatment, SARS-CoV-2, ACE2, coronavirus, Mutation, SARS-COV-2 infection, COVID-19 pandemic, spike glycoprotein, Infection, ACE2 receptor, virus, viral entry, Receptor binding domain, Health, RBD, virus entry, Neutralizing, receptor, virus infection, fusion protein, expression, anti-spike antibody, binding, SARS-CoV-2 spike, Interaction, In-vitro, virus titers, host cells, host cell, acute respiratory syndrome, enzymatic activity, SARS-CoV-2 infected patients, enzyme, problem, specific treatment, SARS-CoV-2-infected patients, block, human IgG1, Extracellular, bind, responsible, caused, physically, globe, composed, inhibit, demonstrated, the RBD, interfere, not affected, fused, inhibit SARS-CoV-2, RBD-Ig, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2 receptor, virus infection, fusion protein, binding domain, neutralize,